Idiopathic Pulmonary Fibrosis Market: Advancing Therapies and Changing Treatment Dynamics
Idiopathic Pulmonary Fibrosis Market Overview Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disorder characterized by persistent scarring of the lungs. As fibrosis advances, lung function progressively declines, making breathing increasingly difficult and significantly affecting patients’ quality of life. The idiopathic pulmonary fibrosis treatment market is undergoing notable transformation as established antifibrotic medicines continue to slow disease progression while newer therapies are being developed to address remaining unmet medical needs. According to DelveInsight, the overall IPF market across the 7MM was valued at approximately USD 3.3 billion in 2023 and is expected to expand during the forecast period through 2036. The assessment covers the United States, EU4, the United Kingdom, and Japan. Idiopathic Pulmonary Fibrosis Disease Burden and Epidemiology IPF predominantly affects older adults and is associated with a gradual decline...